Annual report pursuant to Section 13 and 15(d)

Income Taxes (Tables)

v3.23.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Components of Loss Before Income Tax From Continuing operations

The components of loss before income taxes from continuing operations consist of the following.

 

    2022     2021  
             
United States   $ (15,807 )   $ (18,575 )
Foreign     -       -  
Total loss before income taxes   $ (15,807 )   $ (18,575 )
Schedule of Components of Income Tax Expense Benefit

The Company did not record any current, deferred, or net income tax expense (benefit) from continuing operations in 2022 or 2021. Total income tax expense (benefit) from continuing operations differed from the amounts computed by applying the U.S. federal income tax rate of 21% to pretax income as a result of the following for the years ended December 31:

 

    2022     2021  
Computed “expected” tax expense   $ (3,219 )   $ (3,901)  
Deferred rate change     (132 )     84  
State taxes, net of federal tax effect     (822 )     (752)  
Non-deductible transaction costs     -       222  
Non-deductible interest     2       664  
R&D tax credit     238     (238)  
Sale of vivoPharm business     (72 )        
Other, net     117       (51)  
Change in valuation allowance     3,888       3,972  
Income tax expense (benefit)   $ -     $ -  
Components of Approximate Deferred tax

The tax effects of temporary differences from continuing operations that give rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below as of December 31: 

 

    2022     2021  
Deferred tax assets                
Accrued liabilities   $ 109     $ 47  
Capitalized R&D costs     3,233       1,931  
Intangibles     107       127  
Fixed assets     2       -  
Stock compensation     248       160  
Lease liability     478       170  
Loss carryforward     20,750       18,144  
Tax credit carryforward     1,085       1,406  
Other temporary differences     3       4  
Total gross deferred tax assets     26,015       21,989  
Valuation allowance     (25,614 )     (21,807 )
Total deferred tax assets   $ 401     $ 182  
                 
Deferred tax liabilities                
Fixed assets   $ -   $ (17 )
Lease assets     (401 )     (165 )
Total gross deferred tax liabilities   $

(401

)   $ (182 )
Net deferred tax asset   $ -     $ -